- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05134480
Impact of Donor Diabetes on DMEK Success and Endothelial Cell Loss (DEKS)
Diabetes Endothelial Keratoplasty Study (DEKS): Impact of Diabetes on Corneal Transplant Success and Endothelial Cell Loss
Study Overview
Status
Intervention / Treatment
Detailed Description
This study will address concerns about the suitability of corneas from donors with diabetes for use with DMEK through a prospective, masked, multi-center clinical trial in which the donor corneas are assigned by diabetes status in the same distribution proportion (2:1 distribution of tissue from donors without diabetes to tissue from donors with diabetes) currently used in the USA. The DEKS will assess graft success and endothelial cell density through 1 year following DMEK to determine whether the surgical success rate with corneas from donors with well characterized diabetes (including post-mortem hemoglobin A1c (HbA1c) and advanced glycation endproducts (AGE) testing) is inferior to the rate with donors without diabetes. The investigators hypothesize that the majority of donor corneas from individuals with diabetes will be suitable, but that a portion of donors with a higher diabetes severity scale, and/or poorer control based on HbA1c will have a greater risk for graft failure and endothelial cell loss. This study will also examine collected skin biopsies to determine whether high levels of AGE biomarkers in donor skin tissue - which quantifies disease severity over many years (and possibly coupled with elevated HbA1c levels) - is associated with greater risk for graft failure and cell loss. This novel approach to characterization of donor tissue can provide a paradigm shift in the risk assessment of transplanted corneas from diabetic donors. The effect of recipient diabetes on keratoplasty success and cell loss will also be studied in a rigorous manner to determine the potential combined effect of donor and recipient diabetes status.
In summary, this study is designed to determine if non-diabetic donor corneas are superior to diabetic donor corneas in terms of both graft success and endothelial cell density outcomes, with an additional specific aim to determine whether donors with a higher diabetes severity scale, and/or poorer control based on HbA1c are driving the effect. This study will also determine whether a high AGE/A1c metric is also associated with the potential superiority finding and establish a novel composite score (severity score, HbA1c and AGE/A1c) based on these metrics that can be used to identify high versus low risk diabetic donors. This distinction may enable eye banks to potentially utilize the majority of donors with diabetes for EK surgery, while excluding the severely affected donors with diabetes.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Loretta Szczotka-Flynn, OD, PhD
- Phone Number: 216-844-7984
- Email: Loretta.Szczotka-Flynn@uhhospitals.org
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Recruiting
- Price Vision Group
-
Contact:
- Marianne Price, PhD
- Phone Number: 317-814-2990
- Email: mprice@cornea.org
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49546
- Recruiting
- Verdier Eye Center
-
Contact:
- Paula Johnson, COA
- Phone Number: 1112 616-949-2001
- Email: pjohnson@vecgr.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Participant Inclusion Criteria:
- Age range 30- < 91 years with minimum life expectancy of at least 1 year
- Willingness to return to study site for follow up at 1 month and 1 year
- Fluent in English or Spanish
- Willingness to have fingerstick blood sample collected to determine HbA1c level at entry and at 1 year. The participant must agree to have their primary care provider contacted (or an appropriate referral provided) if they were not known to have diabetes and the HbA1c suggests they may have diabetes. Similarly, if already known to have diabetes and the HbA1c is high, the participant must agree to have their primary care provider contacted or an appropriate referral provided.
- Has at least one eye clinically recommended for DMEK that is able to be scheduled for DMEK between 5 to 90 days after enrollment. If second eye is enrolled, it must be scheduled for DMEK between 7 days and 6 months after DMEK on the first eye.
Has a condition related to endothelial dysfunction which will be treated by DMEK. Eligible indications for DMEK include:
- Presence of Fuchs endothelial corneal dystrophy (FECD) meeting at least one of the following: phakic FECD with or without cataract (triple procedure including DMEK for FECD, cataract extraction and posterior chamber intraocular lens implantation (IOL) is allowed)
- pseudophakic FECD with posterior capsule supported, sulcus supported, or scleral-fixated posterior chamber IOL
- pseudophakic corneal edema with posterior capsule supported, sulcus supported, or scleral-fixated posterior chamber IOL without FECD
- failed Descemet stripping automated endothelial keratoplasty (DSAEK) or DMEK originally performed for the same indications above without current exclusionary criteria, as described below
Exclusion Criteria:
- Pregnant or planning to become pregnant prior to the DMEK study surgery, based on verbal report.
- Lack cognitive capacity such that consent could not be provided.
- Presence of a condition that has a high probability for failure (e.g., failed penetrating keratoplasty, uncontrolled uveitis)
- Stromal vascularization that will impede assessment of recipient stroma clarity
- Other primary endothelial dysfunction conditions including posterior polymorphous corneal dystrophy and congenital hereditary corneal dystrophy.
- Indication for surgery that is not suitable for DMEK (e.g, keratoconus, stromal dystrophies and scars)
- Aphakic corneal edema with or without FECD
- Anterior chamber IOL in study eye prior to DMEK or planned placement of anterior chamber IOL during DMEK
- Presence of vitreous in the anterior chamber
- Planned IOL exchange of an anterior chamber IOL with a posterior chamber IOL in study eye at time of study DMEK
- Pre-operative central sub-epithelial or stromal scarring that could impact post-operative recipient stromal clarity assessment
- Presence of anterior synechiae
- Peripheral anterior synechiae in the angle greater than a total of three clock hours
- Uncontrolled glaucoma with or without prior filtering surgery, tube shunt placement, or MIGS. Uncontrolled glaucoma is defined as intraocular pressure > 25mm Hg.
- Controlled glaucoma with prior tube shunt placement for glaucoma (controlled glaucoma with minimally invasive glaucoma surgery (MIGS) or trabeculectomy is allowed)
- Fellow eye visual acuity < 20/200 due to an ocular condition other than a cornea disease that would be a candidate for DMEK
- Intraocular pressure <8 mmHg
- Topical Rho kinase inhibitor, including netarsudil, used within 1 month prior to study entry and anticipated during the course of the study
- Fellow eye enrolled in the DEKS that has met study-criteria for graft failure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cornea from donor with diabetes
Participant will be assigned a cornea recovered from a donor with diabetes.
|
cornea transplant procedure to replace dysfunctional endothelial cell layer
|
Active Comparator: Cornea from donor without diabetes
Participant will be assigned a cornea recovered from a donor without diabetes.
|
cornea transplant procedure to replace dysfunctional endothelial cell layer
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Graft failure
Time Frame: 1 year
|
Graft failure is defined as the occurrence of one of the following: a graft which requires replacement for any reason or the recipient cornea remains cloudy after surgery without clearing for 8 weeks or longer
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endothelial cell density
Time Frame: 1 year
|
Central corneal endothelial cell density assessed with specular microscopy
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Jonathan Lass, MD, Case Western Reserve University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DEKS
- 1UG1EY030039-01A1 (U.S. NIH Grant/Contract)
- 1UG1EY030030-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fuchs' Endothelial Dystrophy
-
Legacy Health SystemDevers Eye Institute; Lions Eye Bank of Oregon Vision Research Laboratory; Fischer...UnknownFuchs' Corneal Endothelial DystrophyUnited States
-
Kowa Research Institute, Inc.CompletedFuchs' Endothelial Corneal DystrophyUnited States, Australia, Germany, Spain, Denmark
-
Massachusetts Eye and Ear InfirmaryRecruitingFuchs' Endothelial Corneal DystrophyUnited States
-
State University of New York at BuffaloActive, not recruitingFuchs DystrophyUnited States
-
EmmecellActive, not recruitingEndothelial Dysfunction | Corneal Edema | Fuchs Dystrophy | Corneal Endothelial Dystrophy | Bullous Keratopathy | Pseudophakic Bullous Keratopathy | Corneal Endothelial Dysfunction | Fuchs Endothelial Corneal Dystrophy | Moderate Corneal Endothelial DecompensationUnited States
-
Charite University, Berlin, GermanyUnknownEndothelial Dysfunction | Bullous Keratopathy | Fuchs' Endothelial Corneal Dystrophy | Iridocorneal Endothelial Syndrome | Posterior Polymorphous DystrophyGermany
-
Cornea Research Foundation of AmericaCompletedBullous Keratopathy | Fuchs' Endothelial Corneal Dystrophy | Iridocorneal Endothelial Syndrome | Posterior Polymorphous DystrophyUnited States
-
Trefoil Therapeutics, Inc.CompletedEndothelial Dysfunction | Corneal Endothelial Dystrophy | Pseudophakic Bullous Keratopathy | Fuchs Endothelial Corneal DystrophyUnited States
-
Centre Hospitalier Universitaire de Saint EtienneKyoto University, Graduate School of MedicineCompletedFuchs Endothelial Corneal DystrophyFrance
-
Centre Hospitalier Régional Metz-ThionvilleCompletedPseudophakic Bullous Keratopathy | Fuchs' Endothelial Corneal Dystrophy | Descemet Membrane Endothelial Keratoplasty | Graft DetachmentFrance
Clinical Trials on Descemet membrane endothelial keratoplasty
-
Cornea Research Foundation of AmericaCompletedBullous Keratopathy | Fuchs' Endothelial Corneal Dystrophy | Iridocorneal Endothelial Syndrome | Posterior Polymorphous DystrophyUnited States
-
EDUARD PEDEMONTE-SARRIASCompletedFuchs' Endothelial Dystrophy | Corneal Endothelial Cell LossSpain
-
Centre Hospitalier Régional Metz-ThionvilleCompletedPseudophakic Bullous Keratopathy | Fuchs' Endothelial Corneal Dystrophy | Descemet Membrane Endothelial Keratoplasty | Graft DetachmentFrance
-
Charite University, Berlin, GermanyUnknownEndothelial Dysfunction | Bullous Keratopathy | Fuchs' Endothelial Corneal Dystrophy | Iridocorneal Endothelial Syndrome | Posterior Polymorphous DystrophyGermany
-
Fondation Ophtalmologique Adolphe de RothschildNot yet recruitingPatients Undergoing DMEK With a History of Anterior or Posterior Segment Surgery
-
Netherlands Institute for Innovative Ocular SurgeryAmnitrans Eyebank RotterdamCompletedCorneal Dystrophies, HereditaryNetherlands
-
Beyoglu Eye Research and Education HospitalCompletedEndothelial Dysfunction | Fuchs' Endothelial Dystrophy | Pseudophakic Bullous Keratopathy | Herpetic Keratitis | Descemet's Membrane; Defect | Angle's ClassificationTurkey
-
Netherlands Institute for Innovative Ocular SurgeryAmnitrans Eyebank Rotterdam; Melles CorneaClinic RotterdamCompletedCorneal Dystrophies, HereditaryNetherlands
-
University Hospital, AntwerpBelgium Health Care Knowledge CentreRecruitingCorneal Edema | Fuchs' Endothelial Dystrophy | Bullous Keratopathy | Pseudophakic Bullous Keratopathy | Corneal Endothelial DisorderBelgium
-
Alexandria UniversityUnknownPseudophakic Bullous Keratopathy | Anterior Chamber Intraocular LensEgypt